Harmen Beurmanjer

163 Supplements Population description and results Demographics: 70.2% male; 55.7% < 30 years of age; some college or less (58%); unemployed 33.6%. Annual income <$20.000: 37.4%. Other: gay/bi/transgender 26.7% GHB use: life-time GHB-use > 20 times (42.0%); GHB-use while alone (38.2%); driving under the influence of GHB (29.0%); use of a GHB precursor or analogue (27.5%); use of GHB to treat withdrawal symptoms (16.8%); reported GHB related hospital treatment (20%), having sex under influence of GHB (64.1%). Co-ingestion of ethanol or ketamine, driving under the influence of GHB, use of GHB to treat withdrawal symptoms were associated with increased risk of hospital treatment. Other substance use: co-ingestion with alcohol (58%), ecstasy (38.9%), and ketamine (2.9%). Use of heroin ever: 22.1%. Demographics: 47% male; M=23.8, SD=2.9; range 18-32 years; M=23.8, SD=2.9 years of education; 93% was employed and 62% was student; 22% had a stable relationship. GHB use: first use M=21.5, SD=2.9, range 16-28 years; median amount per occasion 3.7ml per dose, 5 doses, 20ml total amount; experienced at least 1 GHB overdose (30 participants - 66.7%); GHB dependent (24%); 60% had never used GHB outdoors, 51% never in a nightlife setting, and 49% never at home at the 10 most recent occasions. Most frequently mentioned setting were a private party or afterparty (less to OD repeat participants). Other substance use: past 30 days: alcohol (100%), at least 1 occasion of ≥ 5 drinks (69%), amphetamines (87%), ecstasy (84%), cocaine (58%), cannabis (71%), ketamine (62%), mushrooms (2%) and LSD (4%). Life-time use: amphetamines (100%), ecstasy (100%), cocaine (100%), cannabis (97.8%), ketamine (82%), mushrooms (47%), and LSD (68%). Rather common was co-use (before or simultaneously) with (Median Likert score 0 – 6) ecstasy (5) and amphetamines (4), whereas co-use of alcohol (2), cocaine (1), cannabis (1) or ketamine (1) was not. Demographics: 76.2% male, M=26.3, SD=9.8 years, 39% employed, Other: 73.8% heterosexual, 9.5% with current psychiatric problems; 9.5% past outpatient psychiatric treatment, 19% past inpatient psychiatric treatment. GHB use: every day (21%), 1 day a week (24%), 1 day a month (20%), <1 per month (17%), other (14%); times per day: 1 (29%), 2-3 (43%), >4 (29%); overdose (26%); treated at ED (9%); physical dependence of GHB (21%), these participants reported use of GHB alone; 7 out of 9 (78%) daily GHB-users had a history of drug problems. Reason GHB use: increased feelings of euphoria, relaxations, and sexuality. Other substance use: Usually co-use reported in 71%: ecstasy (53%), cannabis (50%), cocaine (43%), amphetamine (40%), and alcohol (37%).